Course Description / Needs Statement
The AASLD/FDA DILI Conference — Drug-induced Liver Injury: New Developments and Innovations in Patients with Underlying Liver Disease, Cancer or COVID-19 — will connect international academic, industry and government participants who are dedicated to the study of DILI in chronic liver disease and cancer with topics spanning into innovative tools in the assessment of hepatotoxic risk and the growing number of best practice consensus reports by public-private partnerships management of DILI in different study populations. Additionally, the meeting will have planned sessions on the impact of COVID-19 in the evaluation and management of liver disease. With virtual communication tools, the conference will promote interactivity between faculty and the audience by with panel discussions and a live poster session.
- Mark I. Avigan, MD, CM, FAASLD
- Victor J. Navarro, MD, MHCM, FAASLD
- Robert J. Fontana, MD, FAASLD
- Arie Regev, MD, FAASLD
- Paul H. Hayashi, MD, MPH, FAASLD
- Lorraine Pelosof, MD
- Frank A. Anania, MD, FAASLD
- Paul B. Watkins, MD, FAASLD
The online live-streaming conference will have pre-recorded presentations for viewing along with live elements such as panel discussions, a poster session, and the opportunity to get your faculty questions answered in real time with both Chat and Q&A features available throughout the event.
Poster Abstract Submission
Those interested in drug-induced hepatotoxicity are encouraged to submit poster abstracts for this conference starting Monday, February 1, 2021. To learn more, visit our Abstract Submission and Policies section.
- Continuing Medical Education (CME): 14.00 AMA PRA Category 1 Credits™
- MOC Points: 14.00 ABIM MOC Points
Registration opened Wednesday, March 10. Early bird registration pricing ends on or before Tuesday, April 6, 2021 at 11:59 pm ET.